Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?

In this retrospective cohort study, we aimed to assess whether introducing benznidazole at escalating doses reduces the probability of adverse events or treatment discontinuation compared with a full-dose scheme. We collected data from patients who had chronic " - " infection and underwent...

Descripción completa

Detalles Bibliográficos
Autores: Losada, Irene, Madrid Pascual, Olaya, Herrero Martínez, Juan María, Pérez Ayala, Ana, Lizasoain Hernández, Manuel
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2019
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/135478
Acceso en línea:https://hdl.handle.net/2445/135478
Access Level:acceso abierto
Palabra clave:Malaltia de Chagas
Tripanosoma
Chagas' disease
Trypanosoma
id ES_ee46ace0ea923fa32461a576db11344f
oai_identifier_str oai:diposit.ub.edu:2445/135478
network_acronym_str ES
network_name_str España
repository_id_str
spelling Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?Losada, IreneMadrid Pascual, OlayaHerrero Martínez, Juan MaríaPérez Ayala, AnaLizasoain Hernández, ManuelMalaltia de ChagasTripanosomaChagas' diseaseTrypanosomaIn this retrospective cohort study, we aimed to assess whether introducing benznidazole at escalating doses reduces the probability of adverse events or treatment discontinuation compared with a full-dose scheme. We collected data from patients who had chronic " - " infection and underwent treatment from July 2008 to January 2017 in a referral center in Madrid. Dose was adjusted to body weight (5 mg/kg/day), with treatment introduction with full dose or escalating dose according to local consensus and protocols. Among the 62 patients treated, benznidazole was introduced at full dose in 28 patients and on escalating dose in the remaining 34. We found no statistical differences in the number of adverse events, treatment discontinuations, days of treatment, or sociodemographic profiles. There is insufficient evidence to support escalating dose as a strategy for reducing the adverse effects of benznidazole. Further research is needed to evaluate this strategy.The American Society of Tropical Medicine and Hygiene2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://hdl.handle.net/2445/135478Articles publicats en revistes (ISGlobal)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésVersió postprint del document publicat a: http://dx.doi.org/10.4269/ajtmh.18-0638American Journal of Tropical Medicine and Hygiene, 2019, vol. 100, num. 6, p. 1477-1481http://dx.doi.org/10.4269/ajtmh.18-0638(c) The American Society of Tropical Medicine and Hygiene, 2019info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1354782026-05-27T06:46:51Z
dc.title.none.fl_str_mv Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
title Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
spellingShingle Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
Losada, Irene
Malaltia de Chagas
Tripanosoma
Chagas' disease
Trypanosoma
title_short Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
title_full Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
title_fullStr Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
title_full_unstemmed Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
title_sort Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
dc.creator.none.fl_str_mv Losada, Irene
Madrid Pascual, Olaya
Herrero Martínez, Juan María
Pérez Ayala, Ana
Lizasoain Hernández, Manuel
author Losada, Irene
author_facet Losada, Irene
Madrid Pascual, Olaya
Herrero Martínez, Juan María
Pérez Ayala, Ana
Lizasoain Hernández, Manuel
author_role author
author2 Madrid Pascual, Olaya
Herrero Martínez, Juan María
Pérez Ayala, Ana
Lizasoain Hernández, Manuel
author2_role author
author
author
author
dc.subject.none.fl_str_mv Malaltia de Chagas
Tripanosoma
Chagas' disease
Trypanosoma
topic Malaltia de Chagas
Tripanosoma
Chagas' disease
Trypanosoma
description In this retrospective cohort study, we aimed to assess whether introducing benznidazole at escalating doses reduces the probability of adverse events or treatment discontinuation compared with a full-dose scheme. We collected data from patients who had chronic " - " infection and underwent treatment from July 2008 to January 2017 in a referral center in Madrid. Dose was adjusted to body weight (5 mg/kg/day), with treatment introduction with full dose or escalating dose according to local consensus and protocols. Among the 62 patients treated, benznidazole was introduced at full dose in 28 patients and on escalating dose in the remaining 34. We found no statistical differences in the number of adverse events, treatment discontinuations, days of treatment, or sociodemographic profiles. There is insufficient evidence to support escalating dose as a strategy for reducing the adverse effects of benznidazole. Further research is needed to evaluate this strategy.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/135478
url https://hdl.handle.net/2445/135478
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: http://dx.doi.org/10.4269/ajtmh.18-0638
American Journal of Tropical Medicine and Hygiene, 2019, vol. 100, num. 6, p. 1477-1481
http://dx.doi.org/10.4269/ajtmh.18-0638
dc.rights.none.fl_str_mv (c) The American Society of Tropical Medicine and Hygiene, 2019
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) The American Society of Tropical Medicine and Hygiene, 2019
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv The American Society of Tropical Medicine and Hygiene
publisher.none.fl_str_mv The American Society of Tropical Medicine and Hygiene
dc.source.none.fl_str_mv Articles publicats en revistes (ISGlobal)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423630547419136
score 15,301629

Similares en LA Referencia